- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Sonus names new president
Ultrasound contrast developer Sonus Pharmaceuticals of Bothell, WA, has named Michael Martino as president and COO. Martino will assume day-to-day operational responsibilities formerly held by Sonus founder Dr. Steven Quay, who will remain CEO of the
Ultrasound contrast developer Sonus Pharmaceuticals of Bothell, WA, has named Michael Martino as president and COO. Martino will assume day-to-day operational responsibilities formerly held by Sonus founder Dr. Steven Quay, who will remain CEO of the company and will add chairman to his title. Martino comes to Sonus from the nuclear medicine division of Mallinckrodt of St. Louis, which has a product marketing alliance with Sonus rival Molecular Biosystems.
Emerging Perspectives on PSMA PET Radiotracers: An Interview with Kenneth J. Pienta, MD
April 24th 2024In a recent interview, Kenneth J. Pienta, M.D., discussed the impact of piflufolastat F18, current directions in research with other PSMA-targeted radiotracers and future possibilities for the role of PSMA PET in the imaging paradigm for prostate cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
